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Abstract 
Objective: Nigeria bears 25% of global malaria burden despite concerted efforts towards its control and elimination. 
The emergence of drug resistance to first line drugs, artemisinin combination therapies (ACTs), indicates an urgent 
need for continuous molecular surveillance of drug resistance especially in high burden countries where drug inter‑
ventions are heavily relied on. This study describes mutations in Plasmodium falciparum genes associated with drug 
resistance in malaria; Pfk13, Pfmdr1, PfATPase6 and Pfcrt in isolates obtained from 83 symptomatic malaria patients 
collected in August 2014, aged 1–61 years old from South‑west Nigeria.
Results: Two Pfmdr1, N86 and Y184 variants were present at a prevalence of 56% and 13.25% of isolates respectively. 
There was one synonymous (S679S) and two non‑synonymous (M699V, S769M) mutations in the PATPase6 gene, 
while Pfcrt genotype (CVIET), had a prevalence of 45%. The Pfk13 C580Y mutant allele was suspected by allelic dis‑
crimination in two samples with mixed genotypes although this could not be validated with independent isolation or 
additional methods. Our findings call for robust molecular surveillance of antimalarial drug resistance markers in west 
Africa especially with increased use of antimalarial drugs as prophylaxis for Covid‑19.
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Introduction
Malaria infects over 220 million people with at least 
405,000 deaths annually, 67% of those deaths occur in 
children under the age of five, and 94% of deaths accord-
ing to 2018 World Health Organization data occurred in 
Africa [1]. Drug resistance of malaria parasites to previ-
ously efficacious first line chemotherapies, chloroquine 
(CQ) and sulfadoxine-pyrimethamine (SP), in sub-Saha-
ran Africa (sSA), led to replacement with artemisinin 
combination therapies (ACT), and complete removal 
of CQ [1, 2]. A single point mutation K76T, in codons 
72–76 of the chloroquine resistance transporter gene 
(Pfcrt) has been the main cause of resistance to CQ [3, 4], 
while mutations in the dihydrofolate reductase (DHFR) 
and dihydropteroate synthase (DHPS) were responsible 
for SP resistance in parasites [5, 6].
P. falciparum has also developed resistance to ACTs, 
which combines a fast-acting artemisinin (ART) deriva-
tive with a long-lasting partner such as Lumefantrine, 
Mefloquine or Amodiaquine. ACT resistance is wide-
spread in the Greater Mekong subregion (GMS) in 
southeast Asia [1, 7]. Resistance to ART and its deriva-
tives have been confirmed to be associated with muta-
tions in Kelch-13 gene (pfk13). Mutations in pfk13 have 
been reported in GMS, Guyana, Rwanda, and Tanzania 
[1]. In sSA, pfk13 mutations are yet to be associated with 
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ACT efficacy still remains very high. However, there have 
been increasing case reports of ACT failures, or delayed 
parasite clearance within Africa suggesting the need to 
investigate the factors that might be responsible [8, 9]. 
Mutations in Pfmdr1 on codons 86, 184, 1246 and copy 
number amplifications have also been linked to suscep-
tibility to drugs including ACTs. P. falciparum sarco-
endoplasmic reticulum calcium-ATPase (SERCA) type 
protein encoded by a gene PfATPase6 has been described 
to modulate the susceptibility of parasites to ART. PfAT-
Pase6 protein of P. falciparum has therefore been sug-
gested to be a target of ARTs [10–12].
Molecular surveillance of drug resistance associated 
mutations, especially to ACTs is particularly relevant 
in Africa which bears >   90% of the deaths globally. This 
study describes the molecular prevalence of mutations in 
the drug resistant genes Pfk13, Pfmdr1, PfATPase6 and 
Pfcrt from P. falciparum clinical samples in Southwest 
Nigeria, where Arthemeter Lumefantrine has been the 





This study was carried out in August 2014 in two com-
munities—Badagry (Lagos State) and Alajue (Ede, Osun 
State). Badagry  (6° 25′ N  2° 53′ E), is a coastal town with 
an area of 170  m2 and a human population of 241,093 
(NPC, 2006) that borders the Republic of Benin. Alajue 
village  (7° 40′ N  4° 30′ E), is an ancient Yoruba town with 
a total area of 130 m2 and a human population of 159,866 
(NPC, 2006). Both towns are located in the south western 
part of Nigeria, with similar environmental conditions, 
occupation and lifestyle of the people.
Sampling
A total of 83 symptomatic malaria patients were recruited 
for this study. Following informed consent of the partici-
pants, parent or guardian, they were tested with malaria 
rapid diagnostic test (RDT) kit and 2  ml blood samples 
were collected into RNAlater. Dried blood spots (DBS) of 
each sample was made on 3MM Whatman filter paper.
Nucleic acid extraction
DNA from DBS was extracted using the Qiagen Mini 
Kit (Qiagen) according to manufacturer’s instructions 
and stored at minus 20  °C until needed. Total RNA was 
isolated from whole blood stored in RNAlater using 
PureLink™ RNA Mini Kit (Invitrogen) following the 
manufacturer’s instructions.
Plasmodium falciparum molecular detection
DNA from DBS of each sample was used for molecular 
speciation of P. falciparum by nested PCR through ampli-
fication of the 18S rRNA following established protocols 
[13]. Nest 1 amplified a large part of the 18S rRNA com-
mon to the Plasmodium genus, while the Nest 2 ampli-
fied a region in the genus specific for that species of 
Plasmodia. Differentiation of the species was based on 
amplicon band size with P. falciparum having a size of 
205  bp. PCR fragments were detected and sized on the 
QIAXCEL automated electrophoresis system.
Quantitative PCR
To determine the gene expression levels of Pfk13 and 
PfATPase, total RNA was treated to remove genomic 
DNA by digesting with 2  µl of DNaseI (Fermentas) and 
5 µl of reaction buffer, incubated at 37 °C for 30 min and 
inactivated with 5  µl, 25  mM EDTA, 65  °C for 10  min. 
RNA purity and concentration were determined using a 
NanoDrop 1000TM (Thermo Scientific). cDNA was syn-
thesised using the RNA Reverse Transcriptase kit (Inv-
itrogen). Synthesized cDNA was quantified by qPCR on 
a CFX 96 (Bio-Rad) with the following cyclic conditions: 
95 °C, 10 min, 49 cycles of 95 °C, 15 s and 60 °C for 90 s. 
Relative fold increase of specific mRNA transcripts in 
samples was compared to P. falciparum (3D7) wildtype 
control, normalised using the 18S rRNA housekeep-
ing gene. Expression levels were calculated using  2−ΔΔCt 
method. Data was analysed using at least 3 independent 
experiments.
pfk13 and PfATPase genotyping
Alleles of Pfk13 propeller domain polymorphisms 
(Y493H, R539T, I543T, C580Y), and PfATPase6 (S679S, 
M699V, S769M) associated with delayed clearance 
were determined by Taqman allelic discrimination and 
sequencing and list of primers used provided in Addi-
tional file  1: (Tables S1, 2). For each sample a work-
ing Master Mix was prepared to include 1× of Taqman 
Universal PCR Master Mix (Life Technologies), 300 nM 
of the forward and reverse primers, 200  nM of each 
allele specific probe (Additional file  1: Table  S2) and at 
least 5  ng of DNA from DBS in 25  µl reaction volume. 
Amplification was done on the Bio-Rad CFX96 real-
time thermocycler set to detect fluorescent emissions 
for 6-carboxyfluorescein (6-FAM) (mutant) and hexa-
chloro-6-carboxyfluorescein (HEX) (wild type). Each 
SNP was amplified in a thermocycle of 50  °C for 2 min, 
10 min of initial template denaturation and enzyme acti-
vation at 95 °C followed by 50 cycles of 92 °C for 15 s and 
60  °C for 1 min. Allelic discrimination analysis was per-
formed with the Bio-Rad CFX manager with parameters 
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set to subtract background and correct for fluorescent 
drift prior to clustering of wild or mutant amplicons. All 
PCRs included DNA from P. falciparum 3D7 as wildtype 
control.
Sequencing
Pfk13, PfATPase6, Pfcrt and Pfmdr1 amplicons were 
purified from a 0.8% agarose gel and subjected to cycle 
sequencing using BigDye V3.1 (details in supplementary 
methods section). Sequencing was done on ABI3130XL 
DNA analyser.
Data analysis
Descriptive statistics was carried out in Microsoft Excel 
2010. Sequence alignment was done on CLC Main 
Workbench Version 6.7.1 and translation of nucleotide 
sequence to amino acid sequences and editing were done 
using MEGA 7.0.4 software. A P-value of ≤ 0.05 was con-
sidered statistically significant. Transcript level determi-
nation and allelic discrimination analyses were done with 
the Bio-Rad CFX96 manager software (Additional file 2).
Results
Demographics
In this study, 83 patients, 36 (43.37%) male and 47 
(56.63%) females presenting with symptoms of malaria 
were recruited for the study (Additional file 1: Table S3). 
The age distribution was as follows; 6 (0–5  years), 34 
(6–19 years) 25 (20–35  years) and 18 were > 35 years.
mRNA transcript levels and polymorphisms in Pfk13 
and PfATPase6 genes
Following confirmation of all RDT positive samples 
as P. falciparum positive by PCR, we carried out gene 
expression, detecting only wild type Pfk13 transcript in 
samples. Relatively low levels of PfATPase6 transcript 
was also detected with both wild and mutant strains 
identified in the population (Fig. 1). Probe-specific allelic 
discrimination, detected both wild type and mutant 
PfATPase6 alleles at known drug resistance SNPs (Fig. 2). 
For Pfk13 C580Y locus, mixed alleles (both 580C and 
580Y) were suspected in 2 isolates but the mutant type 
variant was not confirmed by Sanger sequencing of 
amplicons against the reference strain P. falciparum 3D7. 
K13 sequence identified eight non-synonymous SNPs in 
Pfk13, but all in single isolates. A deletion variant A557 
was identified in 3.61% of isolates sequenced (Additional 
file 1: Table S4). 
Distribution and prevalence of PfATPase6, Pfmdr 1 and Pfcrt 
polymorphisms
Sequence analysis of PfATPase6 revealed 3 SNPs, one 
synonymous and two non-synonymous mutations (Addi-
tional file 1: Table S4). The ACT resistance related SNP 
(S769) was present in 3.6% of samples. Pfmdr1 wildtype 
N86 allele was present in 56% of isolates sequenced. 
Pfmdr1 Y184 was at much lower prevalence of 13.25% 
(Additional file  1: Table  S4). Pfcrt 72–76 variants were 
translated, and haplotypes inferred. The CVIET haplo-
type associated with CQ resistance had a prevalence of 
45%, while the wildtype CVMNK was found in 55% of 
isolates from the population (Fig. 3).
Discussion
Chemotherapy is one of the main malaria control strate-
gies implemented by the National Malaria Control pro-
gram in Nigeria. Today, it is mostly based on first line 
Artemisinin based combination therapy that was intro-
duced into Nigeria in 2005 following the withdrawal of 

























Fig. 1 Messenger RNA transcript levels for Pfk13 and PfATPase using  2−ΔΔCt. Total RNA was isolated from whole blood preserved in RNALater, reverse 
transcribed to cDNA in order to measure gene expression profiles
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need to continuously monitor drug resistance and genetic 
markers that are associated with reduced drug efficacy. 
This study characterized drug resistance associated poly-
morphism in four different P. falciparum drug resistance 
genes; Pfcrt, Pfmdr1, PfATPase6 and Pfk13 that have 
been implicated in reduced ACT efficacy [2, 3, 9, 14]. As 
expression of mutated genes is needed for generating the 
resistance phenotype, the allele specific mRNA transcript 
levels of Pfk13 and PfATPase6 were also determined.
Most isolates expressed the wild type Pfk13 while both 
the wild and mutant PfATPase6 variants were expressed 
by different strains. Though Pfk13 C580Y mutant allele 
was suspected in two mixed infections, only wildtype 
mRNA was detected. These mutant variants might have 
been from a minority strain whose mRNA expression 
might have been masked by predominant Pfk13 wildtype 
parasites in the infections. In the absence of repeated 
detection and confirmation by sequencing, the pos-
sibility of the detected Pfk13 C580Y mutants being as a 
result of contamination cannot be ruled out. ACTs have 
been in use for 15  years in Nigeria, and the classical 
South East Asian Pfk13 artemisinin resistance markers 
are rare in Africa. However, the possibility of the Pfk13 
580Y resistance mutations is a call for concern, requir-
ing further sampling and analysis of this population. The 
Pfk13 C580Y mutant is the most prevalent SNP associ-
ated with reduction in parasite susceptibility to ACTs. 
Only few cases of delayed clearance of malaria after ACT 
treatment have been reported in Africa and the C580Y 

















Fig. 2 Allelic discrimination of wild and mutant genes in parasite samples (a) Pfk13 SNP580 and (b) PfATPase SNP402. DNA from dried blood spots 
(DBS) were extracted and used for TaqMan allele discrimination assays. Blue points depict wild type alleles, green for mixed allele calls and orange 


















Fig. 3 Prevalence of Pfcrt polymorphisms in Lagos, Nigeria. Samples were amplified for codons 72–76 using DNA from dried blood spots, 
and amplicons subjected to Sanger sequencing to identify the haplotypes. CVMNK = Cysteine‑Valine‑Methionine‑Asparagine‑Lysine and 
CVIET = Cysteine‑Valine‑Isoleucine‑Glutamic acid‑Threonine at codons 72–76 of the chloroquine resistance transporter gene (Pfcrt)
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efficacy study with patients from the same populations 
detected persistent parasites 3  days post treatment but 
no Pfk13 artemisinin resistance associated mutants [15]. 
Future enlarged studies including in  vivo and in  vitro 
assessments, genetically characterising local parasite iso-
lates may throw light on any possible emergence of toler-
ance to ACT components. Though genetic epidemiology 
and in  vitro forward genetic approaches have clearly 
implicated C580Y and other Pfk13 mutations in delayed 
parasite clearance [16, 17], the artemisinin resistance 
phenotype and associated molecular mechanisms may 
be different in African parasites lacking these Pfk13 vari-
ants. However, a recent report from Rwanda confirmed 
de novo local emergence and spread of the Pfk13 R561H 
artemisinin resistance associated variant, though clinical 
cure rate remained > 95% [18]. Other Pfk13 haplotypes 
containing mutations at positions A578S and V581F, 
close to the C580Y mutation, are known to circulate in 
Africa and could have emerged prior to the introduc-
tion of ACTs [19]. Overall, any molecular indicators of 
resistance to artemisinins should be taken seriously and 
carefully monitored to prevent selection and spread of fit 
resistant parasites across Africa, which heavily relies on 
drugs against high levels of infection and morbidity.
We also detected polymorphisms of PfATPase6, the 
 R37K,  A630S,  I898I found in Brazil, double mutation 
E431K, A623E in Senegal, and  H243Y in Central Africa. 
The PfATPase6 S769 SNP we detected has been widely 
reported as a potential molecular marker for P. falcipa-
rum resistance to artemether [20]. This SNP is found 
within the cytoplasmic N (nucleotide binding) domain 
close to the conserved hinge, which in many species 
is important for structural transitions in the PfATPase 
cycle, calcium binding and release [14].
Other well-known characterized mutations in drug 
resistant genes such as Pfmdr1- N86Y and Y184F, and 
pfcrt- CVIET haplotype were also detected. Polymor-
phisms of Pfmdr1 (N86Y, Y184F, S1034C, N1042D, and 
D1246Y) and copy number amplifications modulate 
resistance to quinolones and other ACT partner drugs. 
They have been associated with reduced efficacy of 
artemether- lumefantrine/mefloquine combinations [21]. 
Artemether-Lumefantrine is the most common ACT 
combination in Africa and Nigeria. It selects for wildtype 
N86 and mutant Y184, as shown for other populations in 
West Africa [22].
Surprisingly a high prevalence of the CVIET haplo-
type was recorded despite the withdrawal of CQ from 
the population almost 10  years prior to this study. The 
high prevalence (45%) observed for Pfcrt-76T resistance 
marker in southwest Nigeria is however lower than those 
reported from the south-eastern part of the country, 
where prevalence was as high as 75% [23]. Lumefantrine 
selects for wildtype Pfcrt K76, reversing CQ resistance 
that is strongly linked to the CVIET haplotype [3]. This 
reversal to the CQ susceptible CVMNK wild type haplo-
type following CQ withdrawal has been reported across 
many malaria endemic regions; in China [24], Tanzania 
[25], Kenya [26] and Malawi [27], or following malaria 
decline as observed in Ghana [28]. Exception are only 
seen in countries like Ethiopia (29) were CQ is still being 
administered to treat P. vivax, maintaining CQ pres-
sure on the parasite to retain the resistant haplotypes. In 
Nigeria, CQ remains accessible through private drug sup-
pliers together with amodiaquine, both of which could 
be slowing the reversal of the resistant haplotype in the 
population.
This study provides a molecular profile of the drug 
resistance genes in malaria parasites from South West-
ern Nigeria, highlighting the need for continuous and 
broader surveillance for antimalarial resistance of this 
high malaria prevalent population.
Limitations
Our limited study locations and sample size is not suf-
ficient to detect emerging resistance loci that may be at 
low frequencies in the populations. Due to limited avail-
ability of sampled DNA and RNA, we were unable to 
repeat the detection of the suspected C580Y mutant or 
validate its presence using sequencing approaches.
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